Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-PRRT Plus Capecitabine in GEP-NETs
NCT02736448Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- May 2016
- Primary completion
- Aug 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started May 2016; status: terminated.
02
Drugs
capecitabine
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT02736448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736448.